APPENDIX 1 - American College of Cardiology



Author Relationships With Industry and Other Entities (Comprehensive)—Surgery for Aortic Dilatation in Patients With Bicuspid Aortic Valves: A Statement of Clarification From the ACC/AHA Task Force on Clinical Practice Guidelines (December 2014)

|Committee Member |Employment |Consultant |Speakers Bureau |Ownership/ |Personal Research |Institutional, |Expert Witness |

| | | | |Partnership/ | |Organizational or Other | |

| | | | |Principal | |Financial Benefit | |

|Loren F. Hiratzka, (TAD |TriHealth Heart Institute—Medical Director,|None |None |None |None |TriHealth Heart Institute* | |

|Chair) |Cardiac Surgery | | | | | | |

|Rick A. Nishimura, |Mayo Clinic, Division of Cardiovascular |None |None |None |None |None |None |

|(VHD Chair) |Disease—Judd and Mary Morris Leighton | | | | | | |

| |Professor of Medicine | | | | | | |

|Mark A. Creager, (TAD |Dartmouth-Hitchcock Medical |None |None |None |None |American Board of Vascular |None |

|Liaison) |Center—Director, Heart and Vascular Center | | | | |Medicine–Trustee† | |

| |and Geisel School of Medicine at | | | | |AHA–President-Elect† | |

| |Dartmouth—Professor of Medicine | | | | | | |

|Robert A. Guyton, (VHD |Emory Healthcare—Professor and Chief, |Medtronic* |None |None |NIH† |None |None |

|Liaison) |Division of Cardiothoracic Surgery | | | | | | |

|Eric M. Isselbacher, |Massachusetts General Hospital—Co-Director |None |None |None |None |None |Defendant, pulmonary |

|TAD |Thoracic Aortic Center; Harvard Medical | | | | | |embolus/ echocardiogram |

| |School—Associate Professor of Medicine | | | | | |interpretation, 2014* |

| | | | | | | |Plaintiff, aortic |

| | | | | | | |dissection, 2014 |

|Lars G. Svensson, |Cleveland Clinic, Heart and Vascular |None |None |None |None |Cardiosolutions |None |

|TAD |Institute—Chairman; Cleveland Clinic Lerner| | | | |Posthorax | |

| |College of Medicine of Case Western Reserve| | | | |ValveXchange | |

| |University—Professor of Surgery | | | | | | |

|Robert O. Bonow, VHD |Northwestern University Feinberg School of |None |None |None |NHLBI—PROMISE trial (DSMB)|Gilead |None |

| |Medicine—Goldberg Distinguished Professor | | | | | | |

| |of Cardiology | | | | | | |

|Thoralf M. Sundt, III |Massachusetts General Hospital—Chief, |None |None |None |Edwards |Thrasos* |Defendant, myocardial |

|VHD |Division of Cardiac Surgery; | | | |LifeScience—Partner trial | |protection, 2014 |

| |Harvard Medical School—Professor of Surgery| | | |(PI) | | |

| | | | | |Medtronic— Perigon trial | | |

| | | | | |(PI) | | |

This table represents all relationships of committee members with industry and other entities that were reported by authors, including those not deemed to be relevant to this document, at the time this document was under development. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$5,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to for definitions of disclosure categories or additional information about the ACC/AHA Disclosure Policy for Writing Committees.

*Significant relationship.

†No financial benefit.

ACC indicates American College of Cardiology; AHA, American Heart Association; DSMB, data safety monitoring board; NHLBI, National Heart, Lung, and Blood Institute; NIH, National Institutes of Health; and PI, principle investigator.

................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download